Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography

Journal of Clinical Oncology

Volumn 23, Issue 21, 2005, Pages 4652-4661

  Juweid, Malik E ^a   Wiseman, Gregory A ^a   Vose, Julie M ^a   Ritchie, Justine M ^a   Menda, Yusuf ^a   Wooldridge, James E ^a   Mottaghy, Felix M ^a   Rohren, Eric M ^a   Blumstein, Norbert M ^a   Stolpen, Alan ^a   Link, Brian K ^a   Reske, Sven N ^a   Graham, Michael M ^a   Cheson, Bruce D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; METHOTREXATE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; RADIOGRAPHY; SCINTISCANNING; TREATMENT OUTCOME;

ADULT; AGED; DISEASE-FREE SURVIVAL; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 23044497490     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.891     Document Type: Article

References (34)

1. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17:1244-1253, 1999
2. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the International Criteria for Neuroblastoma Diagnosis, Staging, and Response to Treatment. J Clin Oncol 11:1466-1477, 1993
3. Fuks JZ, Aisner J, Wiernik PH: Restaging laparotomy in the management of the non-Hodgkin's lymphomas. Med Pediatr Oncol 10:429-438, 1982
4. Stewart FM, Williamson BR, Innes DJ, et al: Residual tumor masses following treatment for advanced histiocytic lymphoma. Cancer 55:620-623, 1985
5. Surbone A, Longo DL, DeVita VT Jr, et al: Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: Significance and management. J Clin Oncol 6:1832-1837, 1988
6. Coiffier B, Gisselbrecht C, Herbrecht R, et al: LNH-84 regimen: A multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 7:1018-1026, 1989
7. Canellos GP: Residual mass in lymphoma may not be residual disease. J Clin Oncol 6:931-933, 1988
8. Kaplan WD, Jochelson MS, Herman TS, et al: Gallium-67 imaging: A predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma. J Clin Oncol 8:1966-1970, 1990
9. 67Ga scintigraphy. Radiology 214:253-257, 2000
10. Vose JM, Bierman PJ, Anderson JR, et al: Single-photon emission computed tomography gallium imaging versus computed tomography: Predictive value in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 14:2473-2479, 1996
11. 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94:429-433, 1999
12. 18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19:414-419, 2001
13. 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun 19:1055-1063, 1998
14. Römer W, Hanauske A-R, Ziegler S, et al: Positron emission tomography in non-Hodgkin's lymphoma: Assessment of chemotherapy with Fluorodeoxyglucose. Blood 91:4464-4471, 1998
15. Kostakoglu L, Goldsmith SJ: Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: Is it time to shift gears? Eur J Nucl Med 27:1564-1578, 2000
16. Juweid M, Wiseman G, Menda Y, et al: FDG-PET predicts with high accuracy the 1-year progression-free survival (1-year PFS) of patients with aggressive non-Hodgkin's lymphoma (NHL) following anthracycline-based first-line chemotherapy. J Nucl Med 43:124P, 2002 (abstr 283)
17. Pieterman R, van Putten JWG, Meuzelaar JJ, et al: Preoperative staging of non-small cell lung cancer with positron-emission tomography. N Engl J Med 343:254-261, 2000
18. 18F] fluoro-2-deoxy-D-glucose: Correlation with CT. Radiology 190:111-116, 1994
19. Avril N, Rose CA, Schelling M, et al: Breast imaging with positron emission tomography and fluorine-18-fluorodeoxyglucose: Use and limitations. J Clin Oncol 18:3495-3502, 2000
20. Tyler DS, Onaitis M, Kherani A, et al: Positron emission tomography scanning in malignant melanoma. Cancer 89:1019-1025, 2000
21. Lowe VJ, Hoffman JM, Delong DM, et al: Semi-quantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 35:1771-1776, 1994
22. Juweid ME, Wiseman GA, Menda Y, et al: Integrated PET based response classification for non-Hodgkin's lymphoma (NH). J Clin Oncol 22:565S, 2004 (abstr 6533)
23. Juweid ME, Wiseman G, Menda Y, et al: Integrated PET plus CT-based response assessment of aggressive NHL. Blood 102:629a, 2003 (abstr 2321)
24. Kostakoglu L, Leonard JP, Coleman M, et al: Evaluation of FDG-ET in the detection of bone marrow involvement in lymphoma. J Nucl Med 41:71P, 2000 (abstr 279)
25. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
26. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data. New York, NY, John Wiley & Sons, 1980
27. Cox DR: Regression models and life tables (with discussion). J R Stat Soc B 34:187-220, 1972
28. Allison PD: Survival Analysis Using the SAS System: A Practical Guide. Cary, NC, SAS Institute Inc, 1995
29. Shipp MA, Harrington DP, Anderson JR, et al: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993
30. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002
31. Lardinois D, Weder W, Hany F, et al: Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348:2500-2507, 2003
32. Freudenberg LS, Antoch G, Schutt P, et al: FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 31:325-329, 2004
33. Allen-Auerbach M, Quon A, Weber WA, et al: Comparison between 2-deoxy-2-[(18)F]fluoro-D-glucose positron-emission tomography and positron-emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol 6:411-416, 2004
34. Goerres GW, von Schulthes GK, Steinert HC: Why most of lung and head and neck cancer will be PET/CT. J Nucl Med 45:66S-71S, 2004 (suppl 1)